Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Steinbach

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Neuroscience Letters|August 7, 2003
Quantification of brain atrophy in patients with myotonic dystrophy and proximal myotonic myopathy: a controlled 3-dimensional magnetic resonance imaging studyJan Kassubek, Freimut D Juengling, Stefanie Hoffmann, et al.
Neuro-Oncology Practice|July 19, 2021
Chemotherapy for adult patients with spinal cord gliomasDorothee Gramatzki, Jörg Felsberg, Bettina Hentschel, et al.
Parasites & Vectors|November 4, 2024
Molecular analysis of vector-borne pathogens in Eurasian badgers (Meles meles) from continental EuropeZoë Tess Lara Lindhorst, Sebastian Brandstetter, Maria Sophia Unterköfler, et al.
Emerging Infectious Diseases|March 19, 2020
Geographic Distribution of Raccoon Roundworm, Baylisascaris procyonis, Germany and LuxembourgMike Heddergott, Peter Steinbach, Sabine Schwarz, et al.
International Journal of Cancer|September 2, 2022
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progressionTheophilos Tzaridis, Johannes Weller, Daniel Bachurski, et al.
American Journal of Human Genetics|January 17, 2003
Expansion of the fragile X CGG repeat in females with premutation or intermediate allelesSarah L Nolin, W Ted Brown, Anne Glicksman, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Journal of Neuro-Oncology|September 20, 2023
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analysesThomas Zeyen, Daniel Paech, Johannes Weller, et al.
Journal of Neuro-Oncology|November 3, 2023
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analysesThomas Zeyen, Daniel Paech, Johannes Weller, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Neuroscience Letters|August 7, 2003
Quantification of brain atrophy in patients with myotonic dystrophy and proximal myotonic myopathy: a controlled 3-dimensional magnetic resonance imaging studyJan Kassubek, Freimut D Juengling, Stefanie Hoffmann, et al.
Neuro-Oncology Practice|July 19, 2021
Chemotherapy for adult patients with spinal cord gliomasDorothee Gramatzki, Jörg Felsberg, Bettina Hentschel, et al.
Parasites & Vectors|November 4, 2024
Molecular analysis of vector-borne pathogens in Eurasian badgers (Meles meles) from continental EuropeZoë Tess Lara Lindhorst, Sebastian Brandstetter, Maria Sophia Unterköfler, et al.
Emerging Infectious Diseases|March 19, 2020
Geographic Distribution of Raccoon Roundworm, Baylisascaris procyonis, Germany and LuxembourgMike Heddergott, Peter Steinbach, Sabine Schwarz, et al.
International Journal of Cancer|September 2, 2022
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progressionTheophilos Tzaridis, Johannes Weller, Daniel Bachurski, et al.
American Journal of Human Genetics|January 17, 2003
Expansion of the fragile X CGG repeat in females with premutation or intermediate allelesSarah L Nolin, W Ted Brown, Anne Glicksman, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Journal of Neuro-Oncology|September 20, 2023
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analysesThomas Zeyen, Daniel Paech, Johannes Weller, et al.
Journal of Neuro-Oncology|November 3, 2023
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analysesThomas Zeyen, Daniel Paech, Johannes Weller, et al.
Pageof 5